Baseline Risk Assessment : Before initiating GLP-1 therapy, clinicians should evaluate baseline fracture risk using established tools such as the FRAX (Fracture Risk Assessment Tool) calculator, which incorporates age, sex, body mass index, prior fractures, family history, and other clinical risk factors
Some people say lower doses feel less restrictive around meals, travel, or social events
Table S1a shows the summary of each metabolite used to obtain the model, and Table S1b shows the performance values of the logistic regression models
When to Contact Your Prescriber Before Restarting Restart without a clinical conversation is risky in several specific situations: You stopped more than 6 months ago and have significant comorbidity changes (new cardiac diagnosis, new medications) You stopped due to pancreatitis, severe gastroparesis, or medullary thyroid carcinoma concerns Your BMI has changed substantially (either direction) You are now pregnant or planning pregnancy (Wegovy is contraindicated in pregnancy per FDA labeling [2]) Any of these situations warrants a new prescriber visit before resuming
In May 2026 the EMAs CHMP issued a positive opinion recommending oral semaglutide 25 mg (the Wegovy pill) for weight management, the first oral GLP-1 of its kind in the EU
